Literature DB >> 22589419

Bupropion and its main metabolite reverse nicotine chronic tolerance in the mouse.

Sheri D Grabus1, Frank Ivy Carroll, Mohamad Imad Damaj.   

Abstract

INTRODUCTION: Although the antidepressant bupropion is prescribed to aid in smoking cessation, little is known concerning its mechanisms of action in this regard. One factor that might influence quit success is nicotine tolerance, which could promote high levels of nicotine intake in order to maintain nicotine's subjective effects (thereby making attempts to reduce smoking more difficult).
METHODS: To explore whether bupropion and its active hydroxymetabolite modulate nicotine tolerance, mice were injected for 14 days with saline or nicotine. On Day 14, animals received saline, (2S,3S)-hydroxybupropion, or bupropion at different doses. On Day 15, mice were assayed on test day for nicotine-induced analgesia and hypothermia.
RESULTS: Animals chronically injected with saline + nicotine developed tolerance to nicotine's effects in both assays. Administration of bupropion and (2S,3S)-hydroxybupropion dose-dependently reversed chronic nicotine tolerance.
CONCLUSIONS: These results indicate that bupropion's ability to promote smoking cessation may be partly due to its attenuation of nicotine tolerance since both measured responses of nicotine (antinociception and hypothermia) are mediated to a large extent by neuronal α4β2* nicotine receptors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22589419      PMCID: PMC3482008          DOI: 10.1093/ntr/nts088

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  29 in total

1.  Naturalistic, self-assignment comparative trial of bupropion SR, a nicotine patch, or both for smoking cessation treatment in primary care.

Authors:  Paul B Gold; Robert N Rubey; Richard T Harvey
Journal:  Am J Addict       Date:  2002

2.  The beta2 but not alpha7 subunit of the nicotinic acetylcholine receptor is required for nicotine-conditioned place preference in mice.

Authors:  Carrie L Walters; Sharon Brown; Jean-Pierre Changeux; Billy Martin; M Imad Damaj
Journal:  Psychopharmacology (Berl)       Date:  2006-01-14       Impact factor: 4.530

3.  Bupropion is a nicotinic antagonist.

Authors:  J E Slemmer; B R Martin; M I Damaj
Journal:  J Pharmacol Exp Ther       Date:  2000-10       Impact factor: 4.030

4.  The effect of bupropion on nicotine craving and withdrawal.

Authors:  S Shiffman; J A Johnston; M Khayrallah; C A Elash; C J Gwaltney; J A Paty; M Gnys; G Evoniuk; J DeVeaugh-Geiss
Journal:  Psychopharmacology (Berl)       Date:  2000-01       Impact factor: 4.530

5.  Reduced antinociception in mice lacking neuronal nicotinic receptor subunits.

Authors:  L M Marubio; M del Mar Arroyo-Jimenez; M Cordero-Erausquin; C Léna; N Le Novère; A de Kerchove d'Exaerde; M Huchet; M I Damaj; J P Changeux
Journal:  Nature       Date:  1999-04-29       Impact factor: 49.962

6.  Nicotine-like discriminative stimulus effects of bupropion in rats.

Authors:  Jenny L Wiley; Kari L Lavecchia; Billy R Martin; M Imad Damaj
Journal:  Exp Clin Psychopharmacol       Date:  2002-05       Impact factor: 3.157

7.  Mecamylamine blocks the development of tolerance to nicotine in rats: implications for the mechanisms of tolerance.

Authors:  S E McCallum; A R Caggiula; L H Epstein; S Saylor; T Ploskina; A F Sved
Journal:  Psychopharmacology (Berl)       Date:  1999-01       Impact factor: 4.530

8.  Modulation of nicotine self-administration in rats by combination therapy with agents blocking alpha 3 beta 4 nicotinic receptors.

Authors:  Stanley D Glick; Isabelle M Maisonneuve; Barbara A Kitchen
Journal:  Eur J Pharmacol       Date:  2002-07-19       Impact factor: 4.432

9.  Characterization of the effects of bupropion on the reinforcing properties of nicotine and food in rats.

Authors:  Adrie W Bruijnzeel; Athina Markou
Journal:  Synapse       Date:  2003-10       Impact factor: 2.562

10.  Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell.

Authors:  Neil E Paterson; David J Balfour; Athina Markou
Journal:  Eur J Neurosci       Date:  2007-05       Impact factor: 3.386

View more
  3 in total

1.  Examination of the metabolite hydroxybupropion in the reinforcing and aversive stimulus effects of nicotine in rats.

Authors:  E Malcolm; F I Carroll; B Blough; M I Damaj; M Shoaib
Journal:  Psychopharmacology (Berl)       Date:  2015-03-13       Impact factor: 4.530

2.  Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state.

Authors:  Neal L Benowitz; Andy Z X Zhu; Rachel F Tyndale; Delia Dempsey; Peyton Jacob
Journal:  Pharmacogenet Genomics       Date:  2013-03       Impact factor: 2.089

3.  The Novel CYP2A6 Inhibitor, DLCI-1, Decreases Nicotine Self-Administration in Mice.

Authors:  Yen-Chu Chen; James P Fowler; Jing Wang; Christy J W Watson; Yasmine Sherafat; Andres Staben; Philip Lazarus; Travis T Denton; Christie D Fowler
Journal:  J Pharmacol Exp Ther       Date:  2019-10-18       Impact factor: 4.030

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.